GJA1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Colorectal Cancer

This article was published in the following Dove Press journal:
Cancer Management and Research

Wenjun Hu^{1,2,*}
Shuchun Li^{1,2,*}
Sen Zhang^{1,2}
Bowen Xie¹
Minhua Zheng^{1,2}
Jing Sun^{1,2}
Xiao Yang^{1,2}
Lu Zang^{1,2}

¹Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; ²Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China

*These authors contributed equally to this work

Purpose: Previous studies found that gap junction alpha-1 protein (GJA1) was a potent tumor suppressor in colorectal cancer (CRC). We designed the present study to evaluate the clinical importance and molecular mechanisms of GJA1 in CRC.

Methods: Clinical and transcriptomic data from TCGA and GEO datasets were retrospectively collected. CRC patients were divided into two subgroups according to the expression level of GJA1 mRNA. Difference between survival time and response to neoadjuvant chemotherapy was then evaluated. Functional assays including wound-healing assay, transwell invasion assay and flow cytometry assay were performed to investigate the effects of GJA1 on invasive ability and response to chemotherapy drugs of CRC cells. Moreover, we explored the mechanisms of GJA1 by which it regulates CRC malignant phenotypes.

Results: The expression level of GJA1 was significantly higher in normal tissue than cancer tissue, indicating a tumor suppressive role of GJA1 in CRC. Patients with higher expression of GJA1 showed better prognosis than those with low GJA1 expression level. Consistently, overexpression of GJA1 suppressed the invasive ability of CRC cells while enhancing the sensitivity of CRC cells to oxaliplatin-induced apoptosis. Mechanically, we found that GJA1 suppressed the epithelial mesenchymal transition process. Moreover, GJA1 could modulating infiltrating levels of several immune cells in the tumor microenvironment.

Conclusion: These findings suggested that GJA1 was correlated with prognosis and immune infiltrating levels of CD8+ T cells, macrophages, neutrophils, and DCs in CRC. In addition, GJA1 expression contributes to regulation of tumor-associated macrophages (TAMs) and tumor infiltrating neutrophils (TINs) in CRC. These findings suggest that GJA1 is a promising biomarker for determining prognosis and immune infiltration in colorectal cancer.

Keywords: colorectal cancer, the gap junction channel protein, metastasis, chemotherapy, immune infiltrates

Introduction

Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide.¹ The high relative mortality is largely due to the ability of CRC to metastasize to remote sites such as the liver and lung.² Although the development of chemotherapy and surgical techniques has been reported,³ the prognosis of metastatic colorectal cancer still remains grim. Therefore, understanding the molecular mechanisms and identify novel treatment target are of great importance.

The initiation and progression of colorectal cancer is thought to result from the accumulation of genetic and epigenetic alterations such as oncogenes and tumor suppressor genes as well as epigenetic changes of additional genes.⁴ Gap junctions

Correspondence: Lu Zang; Xiao Yang
Email zanglu@163.com;
yangxiao19890125@163.com

(GJs) are specific cell-to-cell channels and have an essential role in intercellular communication, adhesion, and cell proliferation by allowing direct exchange of small molecules (<1 kD) and subsequently biologic signaling between adjacent cells.^{5,6} Among GJ family members, gap junction alpha-1 protein (*GJA1*, Connexin43) is the predominant one expressed in epithelial tissues. It has been shown that down-regulation of *GJA1* can result in aggressive growth of breast and lung cancer.⁵⁻⁷ In contrast, forced expression of *GJA1* in various tumor cells can restore normal cell phenotypes and well differentiation.⁸ These findings indicated a possible role of *GJA1* as a tumor suppressor. However, there are limited studies focusing on the role of *GJA1* in CRC. Therefore, understanding the mechanisms by which *GJA1* regulates tumorigenesis or tumor progression may provide a potential target in cancer prevention and therapy.

Accumulating evidence has emphasized that the cross-talk between tumor cells and immune stromal cells is implicated in tumor progression, drug resistance, and clinical outcomes.^{9,10} A previous study defined various types of myeloid cells, such as tumor-associated macrophages (TAMs), tumor-infiltrated neutrophils (TINs), and T cells play important roles in tumor progression and implicated the clinical outcomes.¹¹ For example, infiltration of cytotoxic CD8+ T cells has been associated with a favorable prognosis of CRC patients, mainly because of the anti-tumor activity of CD8+ T cells.¹² Moreover, gastric cancer patients with higher TINs were prone to overall survival benefit from postoperative adjuvant chemotherapy.¹³ However, the role of neutrophils in the tumor microenvironment and the clinical significance of neutrophil infiltration in peri-tumor tissues are controversial. A number of studies have shown that high levels of circulating neutrophils and neutrophil-to-lymphocyte ratio in peripheral blood are associated with poor prognosis in several types of cancer.¹⁴ The above results suggest that the roles and underlying mechanisms of tumor infiltrates in cancer progression and treatment need further investigation.

More importantly, it still remains unclear how genetic alterations in tumor cells could affect the infiltration of stromal cells. In this study, we found that *GJA1* was downregulated in CRC and the loss of *GJA1* is associated with a poorer prognosis and resistance to chemotherapy, confirming the clinical importance of *GJA1* in CRC. Moreover, *GJA1* could re-model the tumor micro-environment by affecting immune infiltrating cells, especially TINs, in the peri-tumor stromal tissue. Our work provided a novel marker for CRC treatment and shed new light on the mechanisms of CRC progression.

Patients and Methods

Acquisition and Processing of TCGA Data

Clinical and transcriptomic data of colon adenocarcinoma (COAD) and rectal carcinoma (READ) were collected from the GDC data portal (<https://portal.gdc.cancer.gov/>) of TCGA database. RNA expression level, copy number variation and methylation level of *GJA1* were extracted and analyzed according to our study design.

Patients and Specimens

A cohort of 75 pairs of human CRC tissues and paired adjacent normal tissues were collected. The experimental study was approved by the Ethic Committee of Shanghai Ruijin Hospital (RJ20180126) and informed consent was obtained from all the cases enrolled in this study. All these patients were diagnosed as CRC pathologically and accepted radical surgery in the Minimally Invasive Surgery Centre, Ruijin Hospital, from 2013 to 2018 and were followed-up for 11 to 62 months. Patients who accepted preoperative treatment such as radiation or chemotherapy were excluded from our study. Cancer and paired normal tissues were embedded with paraffin and were tested with tissue microarray (TMA).

Immunohistochemical (IHC) Analysis

The IHC staining of TMA was performed according to the manufacturer's protocol (Immunostain SP kit, DakoCytomation, USA). Briefly, the tissue sections were deparaffinized and dehydrated, and then treated by 3% H₂O₂ at room temperature for 10 minutes to block endogenous peroxidase activity. Next, the tissue sections were incubated with citrate buffer for the retrieval of the antigen. Then the tissues were blocked with 3% BSA at room temperature for 30 minutes, followed by incubating with proper antibody at 4°C overnight. Two independent pathologists blinded from any data of this study examined the IHC sections. The scoring of *GJA1* protein (Cx43) was based on the proportion of staining (0 = 0%, 1 ≤ 25%, 2 = 25% to 50%, 3 = 51% to 75%, 4 ≥ 75% positive cells) and the staining intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong). The scores for staining intensity and percentage were finally multiplied. An overall score of ≤ 6 was defined as negative, while a score > 6 was defined as positive.

Cell Culture and Transfection

The human CRC cell lines used in our study were purchased from the American Type Culture Collection (ATCC, USA) and preserved in the lab. All these cells were cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS), penicillin (10^7 U/L) and streptomycin (10 mg/L) and incubated at 37°C, 5% CO₂. SW480 and SW48 cells were transfected with a pEX-3 expression vector containing the gene encoding GJA1 (Genepharma, Shanghai, People's Republic of China) or empty pEX-3 vector as control. Lipofectamine 2000 Transfection Reagent (Invitrogen, 11668019) was used according to the manufacturer's instructions.

Western Blot

Western blot analysis was performed as previously described. First, 100 µg of protein was separated by 10% SDS-PAGE gel and transferred to PVDF membranes. The membranes were blocked with 5% bovine serum albumin (BSA) for 2 hours and then were incubated with primary antibodies at 4°C overnight. The primary antibodies included Connexin 43 (C6219, Sigma Aldrich) and EMT sampler kit. Horseradish peroxidase-conjugated secondary antibodies were used and the protein bands were visualized by an enhanced chemiluminescence detection system (Amersham Bioscience, Piscataway, NJ, USA) according to the manufacturer's protocol.

Wound-Healing and Cell Migration Assay

For wound-healing assay, the cells were plated in 6-well plates and grown to approximately 90% confluence. The cells were subsequently starved of serum for 6 hours, and a wound was made by scratching the confluent monolayer with a 200 µl pipette tip. The process of migration was observed and photographed 24 hours after the wounding. The wound size was measured randomly at three sites perpendicular to the wound. Each experiment was replicated three times. For cell migration assay, transwell chamber precoated with 1% collagen I was used (8 µm for a 24-well plate; Corning Costar, NY, USA) to perform cell migration assay. Then, 200 µl serum-free medium containing 10^5 CRC cells was added into the upper transwell chamber while 700 µL RPMI-1640 medium with 20% fetal bovine serum (FBS) was added into the lower chamber. After 24 h incubation, migration cells were fixed with methanol and stained with 0.5% crystal violet for 30

minutes. Finally, the lower side of the chamber membrane were counted and photographed by microscope.

Flow Cytometric Assay

CRC cells were collected and washed with PBS buffer, and then centrifuged for 5 minutes at 1500 rpm. The cells were then resuspended in Binding Buffer and stained for 15 minutes at room temperature using the Annexin V-FITC/PI Apoptosis Kit (BD, USA) according to the protocols. The number of apoptotic cells was detected using BD FACS Vantage System. PI-negative and annexin V-positive cells were considered as early apoptotic (quadrant 3) cells, both PI- and annexin V-positive (quadrant 2) cells were late apoptotic cells. Three independent experiments were performed.

Analysis of Immune Infiltrating Cells

The TIMER online tool is a database which includes 10,897 samples across 32 cancer types from TCGA datasets to estimate the abundance of immune infiltrates. We analyzed GJA1 expression in colorectal cancer and the correlation of its expression with the tumor purity and abundance of immune infiltrates, including B cells, CD4 + T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells, via gene modules. Besides we also evaluated the correlations between GJA1 expression and gene markers of tumor-infiltrating immune cells to investigate the potential mechanisms by which GJA1 attracted these immune cells.

Statistics

Statistical analyses were performed using either a Student's *t*-test or a one-way analysis of variance (ANOVA), according to the characters of data. R software (3.5.2) and GraphPad Prism7 were used to perform data analysis and visualization.

Results

Downregulation of GJA1 Was Associated with Unfavorable Prognosis of CRC Patients

To investigate the role of GJA1 in CRC, we first analyzed the expression of GJA1 in TCGA and GEO public dataset. As shown in [Figure 1A](#) and [C](#), expression of GJA1 was lower in CRC tissue compared with normal tissues, which was consistent with published studies. Moreover, in M1 stage cases, *GJA1* was drastically downregulated ([Figure 1B](#)). The above

Figure 1 GJA1 was a prognostic marker of CRC. (**A** and **B**), RNA-seq data showed that GJA1 was downregulated in colorectal cancer tissues (**A**), especially in M stage cases (**B**). (**C**), Mega-sampler analysis of GEO dataset showed GJA1 was significantly downregulated in CRC tissue. (**D–F**), Kaplan–Meier analysis of TCGA data (**D** and **E**) and GEO data (**F**) showed that high expression level of GJA1 predicted better OS (D and upper panel of **F**) and DFS (E and lower panel of **F**). (**G**), multivariate Cox analysis showed that GJA1 was an independent risk factor of OS. Data were obtained from at least three independent experiments and presented as mean $\pm$ SD; * $P < 0.05$, ** $P < 0.01$ by Students' t -test or Mann–Whitney U -test.

results suggested that *GJA1* was a potent tumor suppressor in CRC and was implicated in chemotherapy response. Next, we evaluated the prognostic value of *GJA1*. As expected, Kaplan–Meier analysis showed that CRC patients with high expression of GJA1 had significantly longer overall survival (OS) than those with lower GJA1 (Figure 1D). Also, the GJA1-high group tended to have a better disease-free survival (DFS) than the GJA1-low group (Figure 1E). Moreover, an external validation cohort from GEO dataset showed

similar results that GJA1 expression was positively associated with better clinical outcomes of CRC patients (Figure 1F). In addition, multivariable Cox regression revealed GJA1 is an independent risk factor of CRC prognosis (Figure 1G).

Based on the results of bioinformatic analysis, we checked and analyzed GJA1 expression in CRC tissues from our cohort containing 75 patients to further investigate the clinical relevance of GJA1 in CRC. In accordance with the results of

the bioinformatic analysis, expression of GJA1 was obviously lower in CRC tissue (Figure 2A–C). We then carried out correlation analysis to assess the relationship between GJA1 expression and clinical parameters by dividing patients into two groups: GJA1 negative (N=50) or GJA1 positive (N=25). Our data showed a negative correlation between GJA1

expression and T stage (Table 1). Because few stage-IV patients were enrolled in the cohort, we did not observe a significant correlation between GJA1 and metastasis. Also, Kaplan–Meier analysis revealed that patients in the GJA1 negative group had significantly poorer OS than those in the GJA1 positive group (log-rank $p = 0.038$, Figure 2D).

Figure 2 Expression level of GJA1 in CRC patients from our cohorts. **(A)** Representative IHC staining of GJA1 in CRC tissues and paired normal tissues from our cohort. **(B)** Expression level of GJA1 in seven cases randomly selected from 75 CRC patients was evaluated by Western blot. **(C)** Statistical analysis of Western blot assay. **(D)** Kaplan–Meier analysis showed that CRC patients with positive GJA1 expression had longer OS time. * $P < 0.05$ by paired Students' t -test.

Table 1 The Relation of GJA1 and Clinicopathologic Parameters in 75 CRC Tissues

Parameters	Case	GJA1 Expression		P-value
		Positive	Negative	
Age				0.8026
<60	30	9	21	
≥60	45	16	29	
Gender				1
Female	46	15	31	
Male	29	10	19	
T stage				0.039
T1+T2	19	10	9	
T3+T4	56	15	41	
N stage				0.67
N0	43	13	30	
N1+N2	32	12	20	
M stage				1
M0	72	24	48	
M1	3	1	2	
Location				0.588
Ascending colon	22	9	13	
Descending colon	9	2	7	
Sigmoid colon	10	2	8	
Rectum	35	13	22	

Note: The stage of CRC was determined by AJCC guideline 8th edition.

Collectively, these data suggested that GJA1 might function as a prognostic marker for both OS and DFS of CRC patients.

GJA1 Suppressed Proliferation and Invasion While Promoted Apoptosis of CRC Cells

To elucidate the underlying mechanisms by which GJA1 regulates the molecular phenotypes of CRC, we overexpressed GJA1 in two CRC cell lines: SW480 and HCT116 cells. As GJA1 is negatively correlated to T stage (Table 1) and M stage (Figure 1B), we presumed that GJA1 might suppress the progression, especially the invasion of CRC cells. To validate this hypothesis, the cell motility was firstly tested with wound healing assay. As shown, compared with the control group, GJA1-overexpressed cells migrated toward the wound more slowly than the negative control cells (Figure 3A, Figure S1A). This result was also confirmed by the transwell migration and invasion assay. We found that migrative and invasive abilities of CRC cells were significantly inhibited upon GJA1 ectopic expression (Figure 3B,

Figure S1B). Next, we detected the changes of epithelial-mesenchymal transition (EMT) pathway, which was a symbol of cell invasion ability, after GJA1 overexpression using Western blot assay. The results showed that epithelial markers such as E-cadherin and ZO-1, were significantly upregulated in GJA1-overexpressed cells, while the expression of mesenchymal markers such as N-cadherin, Snail and Vimentin were decreased (Figure 3C). These results indicated that GJA1 could have impaired the migration and invasion of CRC cells through inhibiting the EMT process.

In addition, to further illustrate the effects of GJA1 on cell viability, we extracted the expression profile of GSE10405 dataset and found GJA1 protein (Cx43) was downregulated in oxaliplatin-resistant cells (Figure 4A). Moreover, the expression level of GJA1 seemed to be lower in CRC patients who did not respond to oxaliplatin-based neoadjuvant therapy (Figure 4B, 4C), which suggested GJA1 might promote oxaliplatin-induced cell apoptosis. The established GJA1-overexpression cell models were incubated with oxaliplatin (15 μ m) for 12 hours and then analyzed with flow cytometric assay. As expected, the apoptotic rate was significantly higher in GJA1 cells than control cells (Figure 4D, Figure S1D). Taken together, these results demonstrate GJA1 acts as a potent tumor suppressor in CRC by suppressing invasion by promoting apoptosis of CRC cells.

GJA1 Modulated the Infiltration of Immune Cells of CRC Microenvironment

Recent studies showed that tumor infiltrated immune cells configure the complicated microenvironment and influence tumor progression and treatment response. Gastric cancer patients with higher tumor infiltrating neutrophils (TINs) were prone to overall survival benefit from post-operative adjuvant chemotherapy.¹³ Other immune cells such as natural killer (NK) cell, dendrite cells (DC) and mast cells are also related to different phases of tumor immune response such as neoantigen presentation and finally affect the response of immunotherapy.^{15–17} We next asked whether GJA1 affected invasive ability and sensitivity of CRC cells to oxaliplatin by regulating the infiltrating level of tumor-associated immune cells. The correlations of GJA1 expression with immune infiltration levels in CRC were assessed by two independent sample cohorts generated by TIMER¹⁸ and TISIDB¹⁹ online tools. The results showed that *GJA1* expression was positively correlated with infiltrating levels of CD8⁺T cells, macrophages, neutrophils, activated NK cells and DC (Figure 5A and B).

Figure 3 In vitro functional assay of GJA1 in CRC cells. **(A)** Wound healing assay of control and GJA1-overexpressed CRC cells. Bar indicates 200 μ m. **(B)** Transwell migration (left panel) and invasion assay (right panel) of control and GJA1-overexpressed CRC cells. **(C)** Expression levels of WNT pathway-associated proteins in control and GJA1-overexpressed were evaluated by Western blots. The statistical analysis is presented in [Figure S1](#).

Moreover, we further measured the relationship of *GJA1* with several chemokines and found that GJA1 was positively correlated with *CCL5*, *CXCL5* and *CXCL8* ([Figure 5C](#)), which were proved to be positively regulated by TAMs and TINs abundance.^{20,21} Most immune cells, including T cells, dendritic cells, and macrophages have been classified into different subpopulations that exert different, even opposite, roles in

different disease contexts.²² TAM has two phenotypes, anti-tumorigenic M1 macrophages and protumorigenic M2 macrophages. Plenty of studies have demonstrated that M2-like macrophages polarization plays a vital role in promoting progression of CRC by activating several oncogenic pathways.²³ Similarly, N1 and N2 neutrophils also display distinct functions in cancer. N1 neutrophils have potent anti-tumor activity

Figure 4 GJA1 promoted apoptosis of CRC cells. **(A)** Downregulation expression of GJA1 protein (Cx43) was observed in oxaplatin-resistant CRC cells. **(B and C)**, RNA-seq and clinical data from TCGA **(B)**, and GEO **(C)** dataset showed that patients responding to neoadjuvant therapy exhibited higher expression of GJA1. **(D)** Flow cytometric assay showed GJA1-overexpressed cells showed better response to oxaplatin. ** $P < 0.01$ by Students' *t*-test or Mann-Whitney *U*-test. Statistical analysis of flow cytometric assay was presented in [Figure S1](#).

mainly due to their release of immunostimulatory cytokines such as *CCL3*, *CXCL9* and *CXCL10* which facilitate recruitment and activation of CD8⁺ T cells.²⁴ We presumed that *GJA1* may increase the infiltration of M1 macrophages and N1 neutrophils. As expected, *GJA1* positively correlated with cell markers of M1 macrophages and N1 neutrophils ([Figure 5D and E](#)), which confirm our hypothesis.

Moreover, we found that *GJA1* also regulated infiltrating levels of T helper cells. As shown, *GJA1* was

positively associated with marker-genes of Th1 cells ([Figure S2A](#)) whereas it was negatively correlated with those of Th17 cells ([Figure S2B](#)), suggesting *GJA1* not only recruited cytotoxic T cells but also enhanced their anti-tumor activity by gathering Th1 cells and expelling Th17 cells. Together, the above results further confirmed the hypothesis that *GJA1* may regulate tumor immune response via interfering with multiple procedures.

Figure 5 GJA1 regulated tumor infiltrating immune cells. (**A** and **B**), correlation analysis of GJA1 expression and tumor infiltrating immune cells performed by TIMER (**A**), and TISDB (**B**) online tools. (**C**) Correlation analysis of GJA1 expression and chemokines. (**D** and **E**), correlation analysis of GJA1 expression and marker genes of M1 macrophages (**D**), and N1 neutrophils (**E**). R values and P values were generated by Pearson correlation test.

Copy Number Variation and Promoter Methylation Led to Downregulation of GJA1 and Alteration of Tumor Infiltrating Immune Cells

As the above results shown, loss of GJA1 promoted progression of CRC and resulted in unfavorable clinical

outcomes. We then tried to investigate the mechanisms of downregulation of GJA1 in CRC. Several molecular events can lead to alterations in gene expression, such as copy number variation (CNV), deletion, and DNA methylation. As shown in Figure 6A, copy number variation and deletion of GJA1 coding gene happened in about 33% CRC cases. Notably, although copy number variation

showed negligible effects on GJA1 expression levels (Figure 6B–C), arm deletion resulted in decreased infiltration levels of CD8+ and CD4+T cells (Figure 6E), which suggested CNV represented a crucial mechanism by which GJA1 regulated tumor infiltrates. Moreover, DNA methylation is negatively correlated with GJA1 levels in CRC (Figure 6D). However, other mechanisms involved

regulations of GJA1 protein, such as protein translation, ubiquitination, or subcellular location, need to be addressed in further studies.

Discussion

Colorectal cancer develops progressively through accumulation of genetic alterations such as activation of

Figure 6 Genomic alterations of *Gja1* gene in CRC tissue. **(A)** OncoPrint showed CNV and mutation of *Gja1* gene in CRC tissue. **(B and C)** Effects of CNV **(B)**, and mutation **(C)** on GJA1 expression. **(D)** Correlation analysis of methylation of *Gja1* gene and GJA1 mRNA level. **(E)** Effects of CNV of *Gja1* gene on infiltration levels of immune cells. Correlation analysis was performed with Pearson correlation analysis. Differences between CNV groups was calculated by one-way ANOVA.

oncogenes and dysfunction of tumor suppressors. It has recently been reported that GJA1 is downregulated and related with relapse-free survival and overall survival in colorectal cancer.²⁵ Interestingly, there is also evidence of correlation of higher level of stromal expression of GJA1 with more advanced clinical stage of CRC.^{26,27} These contradictory findings indicate further investigation of GJA1 as a potential prognostic biomarker in CRC and the underlying mechanisms are warranted.

In the current study, we found the expression of GJA1 in colorectal tissues was significantly decreased compared with non-tumor tissues both in our study and the TCGA cohort. In terms of clinicopathological parameters, the expression of GJA1 was negatively related with the depth of invasion and distant metastasis, suggesting GJA1 might act as a tumor suppressor in CRC by inhibiting metastasis. Moreover, GJA1 expression is identified as a protective factor by multivariate Cox proportional hazards models, which was consistent with previous reports.

Then we investigated the function of GJA1 in CRC in vitro. Our data showed that forced expression of GJA1 significantly inhibited invasive ability of CRC cells, which accounted for the results of clinical-pathological correlation analysis. EMT is a biological process weakening of cell-to-cell adhesion, which enhances the cells migratory capacity and invasiveness.²⁸ Previous studies demonstrated EMT was activated by several signaling pathways and promoted tumor initiation and progression.²⁹ E-cadherin and N-cadherin are two important markers for EMT, which belong to the cadherin family. Loss of E-cad and overexpression of N-cad are usually observed when EMT occurs.²⁸ We assumed that GJA1 might regulate CRC metastasis through modulating EMT because GJA1 was reported to be associated with β -catenin, a key component of the Wnt signaling pathway which could activate EMT. As expected, in our study, we found GJA1 overexpressed inhibiting cell wound healing, migration and invasion of CRC cell lines (Figure 3A and 3B). In addition, immunoblots showed that overexpression of GJA1 promoted expression of epithelial marker E-cadherin, ZO1 whereas decreased mesenchymal marker N-cadherin, Vimentin and Snail (Figure 3C). These results suggested GJA1 acted as a tumor suppressor gene in CRC, and repressed cell migration and invasion through inhibiting EMT. However, how GJA1 downregulated these cell markers requires further investigation.

Another important aspect of this study was GJA1 correlated with diverse immune infiltrating cells in CRC.

Previous studies showed that infiltrated immune cells, including tumor-infiltrating neutrophils (TINs), lymphocytes, and CD8+T cells, were associated with the prognosis of CRC patients and response to checkpoint blockage therapy.^{10,12,30} Here, we reported that GJA1 was correlated with concomitant accumulation of several types of immune cells, including TINs, macrophages, CD8+ T cells and dendritic cells (Figure 5), at the peritumor microenvironment. Recently, there has been emerging interest in exploring the role of TINs in cancers. One study reported that TINs was positively related to prognosis and chemotherapy response in gastric cancer (GC), indicating a protective role of TINs in GC.¹³ However, in another clinical cohort TINs was a risk factor for CRC patients.³¹ Interestingly, in experimental models, TINs can either promote or inhibit tumor progression via releasing cytokines and chemokines, just as tumor-associated macrophages (TAMs).^{20,21} The discrepancy of these studies reveals that there are different subgroups in TINs. It has been documented that neutrophils can polarize into N1 and N2 functional states: N1 neutrophils are antitumorogenic, whereas N2 neutrophils are protumorogenic. In our study, GJA1 is positively correlated with marker genes of N1 neutrophils, which indicated expression of GJA1 in CRC might cause accumulation of N1 neutrophils.

In summary, our results showed that GJA1 is a potential prognosis biomarker in patients with CRC. Besides, we further identified a positive relation between GJA1 and clinical outcomes in patients receiving chemotherapy. The results suggested that among patients receiving adjuvant chemotherapy, those with high GJA1 expression had longer OS compared with those with low GJA1, indicating that GJA1 could be an important factor for predicting the efficiency of chemotherapy. In addition, the ability of GJA1 to suppress CRC may be due to its association with TINs. The study is a retrospective research in nature and the number of patients receiving ACT is relatively small, and the full chemotherapy details were not available for the entire cohorts. Therefore, these results need a prospective, larger, multicentered randomized trial to validate.

Abbreviations

CRC, colorectal cancer; GJA1, gap junction alpha-1; qPCR, quantitative RT-PCR; NC, negative control; TAM, tumor-associated macrophages; TIN, tumor-infiltrating neutrophils.

Ethics Approval and Consent to Participate

All participants provided written, informed consent and no participants had received any medication prior to sample collection under the guidelines of the Ethics Committee of Ruijin Hospital, which approved this study. This study was conducted in accordance with the Declaration of Helsinki.

Acknowledgments

The authors thank all members of the Shanghai Minimally Invasive Surgery Center for assistance in various aspects of this work.

Funding

This study has been supported by National Natural Science Foundation of China (No. 81802933).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7–34. doi:10.3322/caac.21551
2. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet*. 2018;391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-3
3. Asmis TR, Saltz L. Systemic therapy for colon cancer. *Gastroenterol Clin North Am*. 2008;37(1):287–295. doi:10.1016/j.gtc.2007.12.005
4. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. *Breast Cancer Research: BCR*. 2004;6(2):93–101. doi:10.1186/bcr772
5. Gava F, Rigal L, Mondesert O, et al. Gap junctions contribute to anchorage-independent clustering of breast cancer cells. *Bmc Cancer*. 2018;18(1):221. doi:10.1186/s12885-018-4148-5
6. Johnson RD, Camelliti P. Role of non-myocyte gap junctions and connexin hemichannels in cardiovascular health and disease: novel therapeutic targets? *Int J Mol Sci*. 2018;19(3):866. doi:10.3390/ijms19030866
7. Guy S, Geletu M, Arulanandam R, et al. Stat3 and gap junctions in normal and lung cancer cells. *Cancers*. 2014;6(2):646–662. doi:10.3390/cancers6020646
8. Falck E, Klingele K. Expression patterns of Phf5a/PHF5A and Gja1/GJA1 in rat and human endometrial cancer. *Cancer Cell Int*. 2013;13(1):43. doi:10.1186/1475-2867-13-43
9. Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet*. 2018;391(10135):10135. doi:10.1016/S0140-6736(18)30789-X
10. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. *Nat Rev Cancer*. 2016;16(2):121. doi:10.1038/nrc.2016.2
11. Coffelt SB, Wellenstein MD, Visser KED. Neutrophils in cancer: neutral no more. *Nat Rev Cancer*. 2016;16(7):431–446.
12. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Res*. 1998;58(16):3491–3494.
13. Zhang H, Liu H, Shen Z, et al. Tumor-infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. *Ann Surg*. 2016;267(2):1.
14. Wang TT, Zhao YL, Peng LS, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. *Gut*. 2017;66(11):1900–1911. doi:10.1136/gutjnl-2016-313075
15. Caruso RA, Fedele F, Rigoli L, et al. Mast cell interaction with tumor cells in small early gastric cancer: ultrastructural observations. *Ultrastruct Pathol*. 2009;21(2):9.
16. Hans-Gustaf L, Karl-Johan M. Prospects for the use of NK cells in immunotherapy of human cancer. *Nat Rev Immunol*. 2007;7(5):329–339. doi:10.1038/nri2073
17. Mohamed SIA, Jantan I, Nafiah MA, et al. Dendritic cells pulsed with generated tumor cell lysate from *Phyllanthus amarus* Schum. & Thonn. induces anti-tumor immune response. *BMC Complement Altern Med*. 2018;18(1):232. doi:10.1186/s12906-018-2296-4
18. Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Res*. 2017;77(21):e108–e10. doi:10.1158/0008-5472.CAN-17-0307
19. Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. *Bioinformatics*. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/bt210
20. Shao-Lai Z, Zhi D, Zheng-Jun Z, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. *Hepatology*. 2012;56(6):2242–2254. doi:10.1002/hep.25907
21. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. *J Immunol*. 2010;185(4):2273–2284. doi:10.4049/jimmunol.1000901
22. Wang X, Qiu L, Li Z, et al. Understanding the multifaceted role of neutrophils in cancer and autoimmune diseases. *Front Immunol*. 2018;9:2456. doi:10.3389/fimmu.2018.02456
23. Engström A, Erlandsson A, Delbro D, et al. Conditioned media from M1 but not M2 macrophage phenotype inhibits proliferation of the colon cancer cell lines HT29 and CACO-2. *J Biomed Sci*. 2013;2:126.
24. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? *Carcinogenesis*. 2012;33(5):949–955.
25. Wu J-I, Wang L-H. Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application. *J Biomed Sci*. 2019;26(1):8. doi:10.1186/s12929-019-0497-x
26. Radić J, Krušlin B. Connexin 43 expression in primary colorectal carcinomas in patients with stage III and IV disease. *Anticancer Res*. 2016;36(5):2189.
27. Biscanin A, Ljubicic N, Boban M, et al. CX43 expression in colonic adenomas and surrounding mucosa is a marker of malignant potential. *Anticancer Res*. 2016;36(10):5437–5442. doi:10.21873/anticancer.11122
28. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest*. 2009;119(6):1420–1428. doi:10.1172/jci39104
29. Kiesslich T, Pichler M, Neureiter D. Epigenetic control of epithelial-mesenchymal-transition in human cancer. *Mol clin oncol*. 2013;1(1):3–11. doi:10.3892/mco.2012.28
30. Nazemalhosseini-Mojarad E, Mohammadpour S, Torshizi Esafahani A. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: independent of oncogenetic features. *J Cell Physiol*. 2019;234(4):4768–4777. doi:10.1002/jcp.27273
31. Zhao JJ, Pan K, Wang W, et al. The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. *PLoS One*. 2012;7(3):e33655. doi:10.1371/journal.pone.0033655

Cancer Management and Research

Dovepress

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>